Godavari Biorefineries Share Price

Transcript of Earning Call held on 7th August, 2026

• BSE India
• 1 day 7 hours ago

<h3><span style="font-size:16px;"><strong>Specialty Chemicals company Godavari Biorefineries announced Q1FY27 results</strong></span></h3><p _ngcontent-ng-c1940132427=""><strong>Consolidated Financial Highlights:</strong></p><ul><li _ngcontent-ng-c1940132427="">Revenue from operations for Q1FY27 was reported at Rs 55,787.70 lakh, representing a marginal QoQ decrease of 1.10% compared to Rs 56,410.30 lakh in Q4FY26, and a YoY growth of 4.62% from Rs 53,323.63 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427="">Other income for Q1FY27 stood at Rs 204.83 lakh, which declined by 65.27% QoQ from Rs 589.77 lakh in Q4FY26, but grew significantly by 177.58% YoY compared to Rs 73.79 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427="">Total income for the company in Q1FY27 was Rs 55,992.53 lakh, showing a QoQ decrease of 1.77% from Rs 57,000.07 lakh in Q4FY26 and a YoY increase of 4.86% from Rs 53,397.42 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427="">The group reported a loss before tax of Rs 2,584.61 lakh in Q1FY27, as against a profit of Rs 7,027.72 lakh in Q4FY26 and a loss of Rs 2,230.24 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427="">The loss after tax for Q1FY27 stood at Rs 1,931.96 lakh, compared to a profit of Rs 5,288.48 lakh in Q4FY26 and a loss of Rs 1,601.68 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427="">Total comprehensive income for Q1FY27 was a loss of Rs 1,865.48 lakh, compared to a total comprehensive income of Rs 5,554.99 lakh in Q4FY26 and a loss of Rs 1,459.21 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427="">Earnings per share (Basic) for Q1FY27 stood at Rs (3.78) compared to Rs 10.33 in Q4FY26 and Rs (3.13) in Q1FY26.</li></ul><p _ngcontent-ng-c1940132427=""><strong>Standalone Financial Highlights:</strong></p><ul><li _ngcontent-ng-c1940132427="">Revenue from operations in Q1FY27 reached Rs 54,168.09 lakh, reflecting a QoQ decrease of 3.63% from Rs 56,210.57 lakh in Q4FY26 and a YoY increase of 3.55% from Rs 52,312.44 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427="">Other income for Q1FY27 was Rs 182.99 lakh, a decrease of 68.21% QoQ from Rs 575.57 lakh in Q4FY26, while growing by 208.27% YoY from Rs 59.36 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427="">Total income for Q1FY27 stood at Rs 54,351.08 lakh, showing a QoQ decrease of 4.29% from Rs 56,786.14 lakh in Q4FY26 and a YoY increase of 3.78% from Rs 52,371.80 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427="">Profit/(Loss) before tax for Q1FY27 was reported at a loss of Rs 2,823.58 lakh, compared to a profit of Rs 6,957.24 lakh in Q4FY26 and a loss of Rs 2,312.87 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427="">Standalone loss after tax for Q1FY27 was Rs 2,127.40 lakh, compared to a profit of Rs 5,241.13 lakh in Q4FY26 and a loss of Rs 1,664.40 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427="">Total comprehensive income for Q1FY27 was a loss of Rs 2,003.32 lakh, as against a total comprehensive income of Rs 5,195.70 lakh in Q4FY26 and a loss of Rs 1,664.40 lakh in Q1FY26.</li></ul><p _ngcontent-ng-c1940132427=""><strong>Business Highlights:</strong></p><ul _ngcontent-ng-c1940132427=""><li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Segment-wise Performance:</strong><ul><li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Sugar:</strong> The segment revenue for Q1FY27 was Rs 25,341.27 lakh, compared to Rs 54,089.67 lakh in Q4FY26 and Rs 21,981.39 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Cogeneration:</strong> The segment generated Rs 2,448.54 lakh in Q1FY27, compared to Rs 8,276.35 lakh in Q4FY26 and Rs 2,563.22 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427=""><strong>Bio-based Chemicals:</strong> Revenue for this segment was Rs 16,867.10 lakh in Q1FY27, showing growth from Rs 14,735.87 lakh in Q4FY26 and Rs 14,122.04 lakh in Q1FY26.</li><li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Distillery:</strong> This segment recorded a revenue of Rs 15,548.35 lakh in Q1FY27, compared to Rs 22,068.18 lakh in Q4FY26 and Rs 20,700.34 lakh in Q1FY26. It reported an operating loss of Rs 177.38 lakh in Q1FY27.</li></ul></li><li _ngcontent-ng-c1940132427="">The company announced that its 71st Annual General Meeting (AGM) will be held on Monday, September 28, 2026.</li></ul><p><strong>Shri Samir Somaiya, CMD, said:</strong> “Q1FY27 marked an important quarter in strengthening Godavari Biorefineries' integrated platform through strategic execution and operational milestones. During the quarter, we successfully commissioned our 200 KLPD grain-based distillery at Sameerwadi, increasing our total ethanol capacity to 800 KLPD and significantly enhancing our feedstock flexibility. This investment strengthens our ability to optimize operations across varying market conditions while creating a more resilient and future-ready ethanol business.</p><p>Our Bio-based Chemicals business delivered another strong quarter, with robust revenue growth, healthy margin expansion and improved profitability, reflecting the benefits of our debottlenecking initiatives and continued focus on higher-value specialty products. During the quarter, we also secured an Indian patent for a cost-effective process to manufacture branched alcohols, reflecting our continued focus on developing efficient and differentiated technologies.</p><p>Further advancing our innovation pipeline, we filed with the CDSCO to initiate preliminary efficacy trials for our lead anti-cancer molecule targeting Triple Negative Breast Cancer, with trials expected to commence from Q3FY27, subject to regulatory approvals. This marks a significant milestone in translating our R&D efforts into potential clinical applications.</p><p>As we look ahead, our strategic priorities remain centered on expanding our high-value Bio-based Chemicals portfolio, strengthening strategic partnerships and commercialising innovation-led products. We are equally focused on enhancing ethanol fungibility to capitalise on India's evolving biofuel landscape, alongside sustained efforts in R&D and product innovation. These initiatives, supported by our integrated bio-refinery platform, position us well to deliver sustainable long-term growth and value creation.”</p><p><a class="lb" href="/marathi/get-document/post/pdf/5785824/" target="_blank">Result PDF</a></p>

• Trendlyne
• 1 day 14 hours ago

The European Patent Office has granted our patent application titled "Pharmaceutical Composition and Process to Prepare the same"

• BSE India
• 3 days 15 hours ago